



刘国恩 Gordon G. Liu

gordonliu@nsd.pku.edu.cn; Tel: (86) 10 6275-7319; Assistant Ms. Jiang YF: 131-8080-7480

刘国恩，北京大学博雅特聘教授、经济管理学部副主任；北京大学国家发展研究院长江学者特聘教授、学术委员会主任；北京大学全球健康发展研究院院长；北大中国卫生经济研究中心主任。之前，刘国恩教授曾执教美国南加州大学（助理教授），美国北卡大学教堂山分校（副教授），北大光华管理学院（教授）。

刘国恩教授目前为《中美健康二轨对话》中方召集人，全国新冠肺炎专家组经济学家代表，国务院国家医改专家咨询委员会委员，中国药物经济学专业委员会主任委员，联合国秘书长特别顾问 Jeffrey Sachs 领导的《联合国可持续发展行动网络》(SDSN) 领导委员会“人类健康”组联席主席，他曾担任中国留美经济学会主席（2005-2006），国际药物经济学会亚太联合会首任主席（2004-2006）。

刘国恩教授曾先后担任健康经济学国际英文学术期刊《Health Economics》(SCI) 副主编，《Value in Health》(SCI) 副主编，中文《经济学季刊》副主编，《中国药物经济学》期刊创始主编。他的研究方向为健康与发展经济学，国家医疗体制改革，卫生技术评估。2017年，他与美国沃顿商学院教授 Robert Burns 共同出版了《China Healthcare System and Reform》，剑桥大学出版社。

Education and Employment

PhD in Economics, CUNY Graduate Center (1986 -1991)
Post-Doctoral study in Health Economics, Harvard University (1992 -1994)
Assistant Professor, University of Southern California (1994 -1999)
Associate Professor (with tenure), University of North Carolina at Chapel Hill (2000 -2006)
Professor, Peking University Guanghua School of Management (2006 -2013)
MOE Yangtze River Scholar Professor of Economics, PKU National School of Development (2013 - present)
Vice Dean, Peking University Faculty of Economics and Management (2016 – present)

Professional Positions:

Associate Editor, *Health Economics* (SCI) (2013-present)
Founding Editor-in-Chief, *China Journal for Pharmaceutical Economics* (2006-present)
Co-Editor, *Value in Health* (2001-2012)
Co-Editor, *China Economic Quarterly* (2013-2017).

Member, *China National Expert Panel for COVID19* (2020 – present)
Co-organizer, *The US-China Health Dialogue Track II* (2016-present)
Member, *The China State Council Health Reform Advisory Commission* (2011-present)
Board of Directors, *International Society for Pharmacoeconomics and Outcomes Research* (2016-2018);
Co-Chair of *Health Group, The UN Sustainable Development and Solution Network* (SDSN) (2013-present)
Present, *China Society for Pharmacoeconomics and Outcomes Research*, Chinese Pharmaceutical Association (2009-present)
President, *ISPOR Beijing Chapter* (2008-present)
President, *The Chinese Economists Society* (2005-2006);
Founding Chair, *The ISPOR Asian Pacific Consortium* (2004-2006)

Recent Primary Grants:

Gordon G Liu, Principal Investigator, *Economic Experiment of Health Promotion for Poverty Alleviation* (2019-2024), USD\$350,000, founded by the National Science of Foundation, China;

Gordon G Liu, Principal Investigator, *World Management Survey (WMS) based Interventional Study of Chinese Hospital Management* (2017-2022), USD\$71,600, founded by the National Science of Foundation, China;

Gordon G Liu, Principal Investigator, *Chinese Population based Quality of Life Study: An EQ-5D Utility Scoring System* (2013-2018), USD\$83,600, founded by the National Science of Foundation, China;

Gordon G Liu, Principal Investigator, *PKU-CMB Health Economic Research Lab: Health Financing, Delivery, and Economic Prosperity* (2012-2018), USD\$450,000, founded by The China Medical Board, USA.

Recent Work (2008 – present)

Robert Burns (Wharton) and **Gordon G Liu** (PKU), *China's Healthcare System and Reform*, Cambridge Press, 2017.

Gordon G. Liu, Editor-in-Chief, *China Guidelines for Pharmacoeconomic Evaluations*, 2020 (Chinese-English Version)

1. Nie P. et al., "Income-related health inequality among Chinese adults during the COVID-19 pandemic," *International Journal for Equity in Health*, forthcoming, 2021.
2. Chen C., **Liu GG.**, et al., "Association between household fuel use and sleep quality in the oldest-old: Evidence from a propensity-score matched case-control study in Hainan, China," *Environmental Research*, 17 Sep 2020, 191:110229.
3. Shi W, Wouters O., **Liu GG.**, et al., "Association between provincial income levels and drug prices in China over the period 2010-2017," *Social Science and Medicine*, 05 Aug 2020, 263:113247.
4. **Liu GG.** et al., "Does Ownership Matter for Medical System Performance? Evidence from a Natural Experiment in Suqian, China," *Inquiry*, 2020, 57(5)
5. Myerson R., **Liu GG.**, et al., "The Impact of Government Income Transfers on Tobacco and Alcohol Use: Evidence from China," *Economic Letters*, Jan 2020, 186: 108855.
6. Yao Y., **Liu GG.**, et al., "On-the-job training and organizational performance: Analyses from medical institutions in China," *China Economic Review*, April 2020, 60: 101396.
7. **Liu GG.**, Wu E. et al., "The Development of Health Technology Assessment (HTA) in Asia: Current Status and Future Trends," *Value in Health Regional Issues*, May 2020, 21: 39-44.
8. Wang MX., **Liu GG.**, et al., "The role of mediation committee in solving medical disputes in China," *BMC Health Services Research*, 2020, 20, 225.
9. Zhou Qin, Qin XZ, and **Liu GG.**, "Relative Income and Mental Health among Chinese Adults: Evidence from the China Health and Retirement Longitudinal Study," *Review of Development Economics*, July 1, 2020.
10. Chen C., **Liu GG.**, et al., "Health-Related Quality of Life and Associated Factors Among Oldest-Old in China," *J of Nutrition, Health & Aging*, January, 2020.
11. Butt T, **Liu GG.** et al., "Taking stock of cost-effectiveness analysis of healthcare in China," *BMJ Global Health*, 2020, 4:e001418.
12. Yao Y, **Liu GG.** et al., "Disease and disparity in China: a view from stroke and MI disease," *International J for Equity in Health*, June 11, 2020.

13. Guan H, **Liu GG.**, et L., “Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer in China,” *Clinical Therapeutics*, 2019, 41(11): 2308-2320.
14. **Liu GG.** and Chen Xi, “China in transition: health, wealth, and globalization,” *The LANCET Public Health*, September 2019.
15. Myerson R., **Liu GG.**, et al., “Cancer Diagnosis and Care among Rural-to-Urban Migrants in China,” *BMJ Global Health*, 2019;4:e001923.
16. Koch M., Butt T., **Liu GG.** et al., “Characteristics and health burden of the undiagnosed population at risk of chronic obstructive pulmonary disease in China,” *BMC Public Health*, 2019, 19, 1727.
17. **Liu GG.**, Shepherd J. et al., “Characteristics of Patients with Dyslipidemia Treated in Routine Care Setting in China,” *Journal of Drug Assessment*, Oct 2019, 8(1):192-198.
18. Shang P, **Liu GG.** et al., “Association Between Medication Adherence and 1-year Major Cardiovascular Adverse Events After Acute Myocardial Infarction in China,” *JAMA*, 2019 May 7;8(9):e011793.
19. Wang Pei, **Liu GG.** et al. “Valuation of EQ-5D-5L Health States: A Comparison of Seven Asian Populations,” *Expert Review of Pharmacoeconomics & Outcomes Research*, 2019, 19(4).
20. An RP, **Liu GG.**, et al., “Dietary habits and cognitive impairment risk among oldest-old Chinese,” *Journal of Gerontology: Social Sciences*, 2019, 74(3): 474-483.
21. 陈晨, 刘国恩等, “中国老人接种流感疫苗的成本效果分析”, 《中华预防医学杂志》, 2019
22. 王梦潇, 刘国恩等, “中国医院管理调查中人才管理的现状分析”, 《中国医院管理》, 2019
23. 王雅楠, 刘国恩等, “溶栓治疗急性心肌梗死的药物经济学研究”, 《中国药物经济学》, 2019
24. Shi J, Yao Y., and **Liu GG.**, “Modeling Individual Healthcare Expenditures in China: Evidence to Assist Payment Reform in Public Insurance,” *Health Economics*, 2018, 27(12):1945-1962.
25. Jin XJ., Gerstein HC, **Liu GG.**, et al. “Minimally important difference and predictors of change in quality of life as measured using the EQ-5D among Chinese Type 2 Diabetic Patients: A community-based survey in China,” *Diabetes/Metabolism Research and Reviews*, 2018, July.
26. Li Hong, **Liu GG.**, et al., “Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions,” *Value in Health Regional Issues*, 2018: 133-137.
27. Jin X, **Liu GG.**, Gerstein HC, Levine MAH, Steve K, Guan H, Li H, Xie F, “Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL),” *Health Qual Life Outcomes*, 2018, 16:78
28. An RP, **Liu GG.**, et al., “Dietary habits and cognitive impairment risk among oldest-old Chinese,” *Journal of Gerontology: Social Sciences*, 2017.
29. Hu XF, **Liu GG.**, and Fan M., “Long-Term Effects of Famine on Chronic Diseases: Evidence from China’s Great Leap Forward Famine,” *Health Economics*, 2017, 26(7): 922–936.
30. **Liu GG.**, Vortherms SA., and Hong XZ, “China’s health reform update,” *Annual Review of Public Health*, 2017, 38: 431-448.
31. **Liu GG.**, “Building A National Health System,” *China Economic Quarterly*, 2017, 21(1): 16-23.
32. **Liu GG.**, et al., “How Much Does Social Status Matter to Longevity? – Evidence from China’s Academician Election,” *Health Economics*, 2017, 26(3):292-304.

33. Luo N., **Liu GG.** Li M., Guan H, Jin X, and Rand-Hendriksen K., "Estimating an EQ-5D-5L value set for China," *Value in Health*, 2017 Apr;20(4):662-669.
34. Zhou Q., **Liu GG.**, Krumholz S., "Is Chinese National Health Insurance Effective in the Face of Severe Illness? A Perspective from Health Service Utilization and Economic Burden," *Social Indicators Research*, 2016: 1-23.
35. Fan M, Lei Z, and **Liu GG.**, "Discounting of Medical Savings Accounts," *American J of Health Economics*, 2016(4): 161-183.
36. Xuejing Jin., **Liu GG.**, et al., "Is bad living better than good death? Impact of demographic and cultural factors on health state preference," *Quality of Life Research*, 2016, 25(4): 979-986.
37. **Liu GG.**, Xue XD., Yu C., Wang YF., "How does social capital matter to the health status of older adults? Evidence from the China Health and Retirement Longitudinal Survey," *Economics and Human Biology*, 2016, 22: 177-189.
38. Zhou Qin, **Liu GG.** et al., "The Impact of Health Insurance Cost-Sharing Method on Healthcare Utilization in China," *China Journal of Social Work*, 2016, 9(1): 38-61.
39. Stevens W., **Liu GG.**, et al., "Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China," *BMC Health Services Research*, 2016, 16(1):175.
40. An RP and **Liu GG.**, "Cognitive Impairment and Mortality among the Oldest-old Chinese," *International Journal of Geriatric Psychiatry*, 2016, 31: 1345-1353.
41. Pan J., Lei XY, and **Liu GG.**, "Health Insurance and Health Status: Exploring the Causal Effect from A Policy Intervention," *Health Economics*, 2016, 25:1389-1402.
42. Li Q, **Liu GG.**, and Zang WB, "The Health of Left-behind Children in Rural China," *China Economic Review*, 2015, 36:367-376.
43. Wang P, Li MH, **Liu GG.**, Thumboo J., and Luo N, "Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese," *European J of Health Economics*, 2015 (16): 857-863.
44. Xu J., **Liu GG.** et al., "A comparison of outpatient healthcare expenditures between public and private medical institutions in urban China: an instrumental variable approach," *Health Economics*, 2015(24): 270-279.
45. Barredo L, Agyepong I, **Liu GG.** and Reddy S, "Ensure healthy lives and promote well-being for all at all ages," *UN CHRONICLE*, 2014: No. 4.
46. **Liu GG.**, Chen YQ, and Qin XZ., "Transforming rural healthcare through information technology: an interventional study in China," *Health Policy and Planning*, 2014 (8): 975-985.
47. **Liu GG.** and Krumholz S., "Economics of health transition in China," *The Oxford Companion to the Economics of China*, edited by Ravi Kanbur et al., Oxford University Press, 2014.
48. Qin XZ, Pan J, and **Liu GG.**, "Does participating in health insurance benefit the migrant workers in China? an empirical investigation," *China Economic Review*, 2014 (30): 263-278.
49. DiBonaventura M, Yuan Y, Lescauwat B, L'Italien G, **Liu GG.**, "Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: A patient survey," *PLOS ONE*, Jan 21, 2014.
50. Wu J., Xu J., **Liu GG.**, "Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals," *PharmacoEconomics*, 2014 (32):293-303.
51. Gao C., Xu F., **Liu GG.**, "Payment reform and changes in health care in China," *Social Science & Medicine*, 2014 (111): 10-16.
52. Chen G, **Liu GG.**, and Xu F., "The impact of the urban resident basic medical insurance in China on health services utilization," *PharmacoEconomics*, 2014 (32): 277-292.

53. Li H., **Liu GG.**, Glaetzer C., "Financing innovative medicines in China: the role of commercial health insurance," *Chinese Studies*, 2013 (3): 128-133.
54. Pan J., **Liu GG.**, and Gao C., "How does separating government regulatory and operational control of public hospitals matter to healthcare supply?" *China Economic Review*, 2013 (27):1–14.
55. Lai W, Hu S., Hou J, **Liu GG.**, "A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity and healthcare costs of chronic hepatitis B in China," *Value in Health Regional Issues*, 2013 (2):48-56.
56. Pan J, Qin X, **Liu GG.**, "The impact of body size on urban employment: evidence from China." *China Economic Review*, 2013 (27): 249-263
57. Luo N, Li M, **Liu GG** et al., "Developing the Chinese version of the new 5-level EQ-5D descriptive system: the response scaling approach," *Quality of Life Research*, 2013(4): 885–890.
58. Qin XZ and **Liu GG.**, "Does the U.S. healthcare safety net discourage private insurance coverage?" *European J of Health Economics*, 2013 (3): 457-469.
59. Liu YJ, Xue YJ, Liu GG., and Ma AX., "Development of foreign invested hospitals in China: obstacles and coping strategies," *Journal of Hospital Administration*, 2013(2): 142-150.
60. Zhao ZY, **Liu GG.**, et al., "Hospital costs of adverse events in patients with metastatic colorectal cancer," *Journal of Cancer Therapy*, 2013 (4): 153-158.
61. **Liu GG** et al., "The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan," *Value in Health*, 2012, 15(1).
62. Pan Jay and **Liu GG.**, "The determinants of Chinese provincial government health expenditures: evidence from 2002-2006 data," *Health Economics*, 2012(21): 757 - 777.
63. Qiu Y., Fu A, **Liu GG.**, and Christensen D., "Healthcare Costs of Atypical Antipsychotic Use for Patients with Bipolar Disorder in a Medicaid Program," *Applied Health Economics and Health Policy*, 2010, 8(3):167-177.
64. **Liu GG.**, Zhang SF ,and Zhang ZY., *Investing in Human Capital for Economic Development in China*, published by World Scientific, 2010.
65. **Liu GG.**, Fukuda T., Lee CE. et al., "Evidenced-based Decision Making on Medical Technologies in China, Japan, and Singapore," *Value in Health*, 2009, 12(3): S12 - S17.
66. **Liu GG.**, Li L., Hou X. et al., "The role of for-profit hospitals in medical expenditures: evidence from aggregate data in China," *China Economic Review*, 2009, 20: 625-633.
67. Lin W., **Liu GG.**, and Chen G., "The Urban Resident Basic Medical Insurance: a landmark reform towards universal coverage in China," *Health Economics*, 2009, 18:S83-S96.
68. **Liu GG.**, "Beijing's perspective: the internal debate on health care reform," published by the Center for Strategy and International Studies (CSIS), Washington DC., 2009.
69. Qiu Y, Christensenb D, Fu AZ, and **Liu GG.**, "Cost analysis in a Medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy," *Current Medical Research and Opinion*, 2009, 25(2): 351–361.
70. **Liu GG.**, Eggleston K., and Hu TW., "Emerging health economics and outcomes research in Asian Pacific Region," *Value in Health*, 2008, 11:s1-s2.
71. **Liu GG.**, Dow W., Fu AZ., Akin J., and Lance P., "Income productivity in China: on the role of health," *Journal of Health Economics*, 2008, 22: 22-44.